<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04672018</url>
  </required_header>
  <id_info>
    <org_study_id>CRO-002-TCM-HTJWT-2019</org_study_id>
    <nct_id>NCT04672018</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Houtou Jianweiling Tablet in the Treatment of Chronic Non-Atrophic Gastritis</brief_title>
  <acronym>CT</acronym>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Non-inferiority Clinical Trial on the Efficacy and Safety of Houtou Jianweiling Tablet in the Treatment of Chronic Non-Atrophic Gastritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Karachi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indus Hospital and Health Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Xinhui Pharmacy Limited Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Karachi</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the efficacy &amp; safety of Houtou Jianweiling tablet through the non-inferiority&#xD;
      clinical trial of Houtou Jianweiling tablet with Omeprazole Enteric-coated tablet in patients&#xD;
      with chronic non-atrophic gastritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title:&#xD;
&#xD;
      Randomized, Double-Blind, Placebo-Controlled, Non-inferiority Clinical Trial on the Efficacy&#xD;
      and Safety of Houtou Jianweiling Tablet in the Treatment of Chronic Non-Atrophic Gastritis&#xD;
      Test Center: Multi-center Objective: To study the efficacy &amp; safety of Houtou Jianweiling&#xD;
      tablet through the non-inferiority clinical trial of Houtou Jianweiling tablet with&#xD;
      Omeprazole Enteric-coated tablet in patients with chronic non-atrophic gastritis.&#xD;
&#xD;
      Experimental Design: Randomized, double-blind, placebo-controlled, non-inferiority trial's&#xD;
      efficacy and safety shall be adopted in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Double-Blind, Placebo-Controlled, Non-inferiority Clinical Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Scale for pain (VAS)</measure>
    <time_frame>During the four-week trial period</time_frame>
    <description>Gastric pain assessment （VAS score): Applying the Visual Analogue Scale (VAS) i.e. 0-10 Numeric Pain Intensity Scale on a 10 cm line segment, 0 is painless, 10 is extremely painful, patients will marked in the corresponding position according to the degree of pain, and the amount of the researcher give a specific score. The grading criteria of gastralgia with VAS score will be, normal: 0 cm; mild: 1-3 cm; moderate: 4-6 cm; severe: 7-10 cm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physicians Global Assessment to measure quality of life (PGA)</measure>
    <time_frame>During the four-week trial period</time_frame>
    <description>Therapeutic efficacy evaluation by secondary symptoms i.e. Gastric Distension on 0-6 points scoring system e.g.&#xD;
0 point: None before treatment or disappeared after treatment 2 points: Slight gastric distension, from time to time, does not affect work and rest.&#xD;
4 points: Gastric distension can tolerable, attacks frequently, affecting work and rest.&#xD;
6 points: The gastric distension is intolerable and persist for a long time. Often needs pain killer to relief pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Indicates of liver function</measure>
    <time_frame>4 weeks treatment</time_frame>
    <description>Routine blood tests for liver function (alanine aminotransferase ALT, aspartate aminotransferase AST, gama γ-glutamyltransferase GGT, alkaline phosphatase ALP, total bilirubin T.BIL),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Helicobacter pylori eradication rate</measure>
    <time_frame>During the 4 weeks treatment period</time_frame>
    <description>H. pylori test (C13 breath test)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>During the 4 weeks treatment period</time_frame>
    <description>blood pressure</description>
  </other_outcome>
  <other_outcome>
    <measure>Body Temperature</measure>
    <time_frame>During the 4 weeks treatment period</time_frame>
    <description>body temperature</description>
  </other_outcome>
  <other_outcome>
    <measure>vital signs</measure>
    <time_frame>During the 4 weeks treatment period</time_frame>
    <description>pulse rate, respiration rate</description>
  </other_outcome>
  <other_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>within 10 days before enrollment and within 5 days after the end of treatment</time_frame>
    <description>ECG QT Interval evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal function</measure>
    <time_frame>within 10 days before enrollment and within 5 days after the end of treatment</time_frame>
    <description>BUN, Cr</description>
  </other_outcome>
  <other_outcome>
    <measure>Stool tests</measure>
    <time_frame>within 10 days before enrollment and within 5 days after the end of treatment</time_frame>
    <description>Stool occult blood test</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Gastritis</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Houtou Jianweiling tablet (0.38 g), 4 tablets taken orally at a time, 3 times a day and Omeprazole Enteric-coated placebo tablet, taken 1 tablet orally once a day before breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omeprazole Enteric-coated tablet (20 mg), 1 tablet taken orally once a day before breakfast and Houtou Jianweiling placebo tablets, taken orally, 4 tablets at a time, 3 times a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Houtou Jianweiling tablet,</intervention_name>
    <description>The raw materials of Houtou Jianweiling Tablet are safe and effective. It has been used and marketed in China for nearly 20 years without toxic reactions and adverse events. The composition of the prescription conforms to the theory of traditional Chinese medicine and is supported by 20 years of clinical application experience.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>Traditional Chinese Medicine (TCM)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  (1) Comply with the diagnostic criteria for chronic non-atrophic gastritis.&#xD;
&#xD;
          -  (2) Age between 18 to 65 years.&#xD;
&#xD;
          -  (3) Voluntarily participate the clinical trials and sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) Subjects with history of gastric surgery.&#xD;
&#xD;
          -  (2) Patients with complicated and special types of gastritis, peptic ulcer,&#xD;
             hemorrhage, cholecystitis, cholelithiasis, dysplasia of gastric mucosa or pathological&#xD;
             diagnosis of suspected malignant change.&#xD;
&#xD;
          -  (3) Patients with atrophy and/or intestinal metaplasia through pathological&#xD;
             examination showed;.&#xD;
&#xD;
          -  (4) Severe primary diseases associated with cardiovascular, cerebrovascular, lung,&#xD;
             liver, kidney and hematopoietic system (above grade II of cardiac function; ALT&amp;AST&#xD;
             are 1.5 times higher than the normal value; Cr value above the upper limit of normal&#xD;
             value), or serious diseases affecting their survival, such as cancer or AIDS;&#xD;
&#xD;
          -  (5) Positive stool occult blood patients;&#xD;
&#xD;
          -  (6) Patients who have used Chinese and Western medicine to treat chronic non-atrophic&#xD;
             gastritis in the last two weeks;&#xD;
&#xD;
          -  (7) Subjects with psychiatric disorders or a history of alcohol/drug abuse;&#xD;
&#xD;
          -  (8) Pregnant women, woman who are preparing for pregnancy, lactating women;&#xD;
&#xD;
          -  (9) Patients who are allergic constitution or allergic to known ingredients of test&#xD;
             drugs;&#xD;
&#xD;
          -  (10) Those who have participated in or are participating in other drug clinical trials&#xD;
             in the past 3 months;&#xD;
&#xD;
          -  (11) The syndrome differentiation is not clear or there are too many and complicated&#xD;
             syndromes for the subjects;&#xD;
&#xD;
          -  (12) Subjects that researchers do not consider appropriate to participate in clinical&#xD;
             trials.&#xD;
&#xD;
          -  (13) Patients with poor compliance are not allowed to participate in this trial.&#xD;
&#xD;
               -  Those who meet one or more of the above exclusion criteria cannot be included in&#xD;
                  the clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Muhammad Raza Shah</last_name>
    <phone>+922199261717</phone>
    <email>raza_shahm@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Bioequivalence Studies and Clinical Research (CBSCR), ICCBS, university of Karachi</name>
      <address>
        <city>Karachi</city>
        <zip>75270</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Raza Shah, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 28, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Karachi</investigator_affiliation>
    <investigator_full_name>Dr. Muhammad Raza Shah</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

